QCI Asset Management Inc. NY lifted its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 6.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 231,766 shares of the biopharmaceutical company’s stock after buying an additional 14,110 shares during the period. QCI Asset Management Inc. NY’s holdings in Bristol-Myers Squibb were worth $12,914,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of BMY. Ameriprise Financial Inc. raised its stake in Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares during the period. Swiss National Bank raised its stake in shares of Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after acquiring an additional 1,267,900 shares during the period. State Street Corp raised its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the period. Jennison Associates LLC grew its holdings in Bristol-Myers Squibb by 5.4% during the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after purchasing an additional 1,184,652 shares in the last quarter. Finally, Harbour Capital Advisors LLC grew its holdings in Bristol-Myers Squibb by 5,377.1% during the 2nd quarter. Harbour Capital Advisors LLC now owns 1,189,789 shares of the biopharmaceutical company’s stock valued at $21,353,000 after purchasing an additional 1,168,066 shares in the last quarter. 69.51% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.25 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The stock has a market cap of $99,822.34, a PE ratio of 20.60, a PEG ratio of 2.40 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the previous year, the business posted $0.77 earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were given a $0.39 dividend. The ex-dividend date was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.55%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.
A number of equities research analysts recently weighed in on BMY shares. Credit Suisse Group reaffirmed a “hold” rating and set a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Cowen and Company reaffirmed a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group LLC raised their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Finally, Leerink Swann raised their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $64.93.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.